Antiarrhythmic Drugs Market Size, Share & Trends Report

Antiarrhythmic Drugs Market Size, Share & Trends Analysis Report By Drug Class (Beta Blockers, Sodium Channel Blockers), By Route of Administration (Oral, Parenteral), By Distribution Channel, By Region, and Segment Forecasts, 2025 - 2030

Report ID: GVR-4-68040-479-7
Number of Report Pages: 120
Format: PDF, Horizon Databook

Historical Range: 2018 - 2024
Forecast Period: 2025 - 2030
Industry: Healthcare

Market Segmentation

Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
- Sodium Channel Blockers
- Beta Blockers
- Potassium Channel Blockers
- Calcium Channel Blockers
- Other
Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Oral
- Parenteral
- Other
Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
- Hospital Pharmacies
- Retail Pharmacies
- Other
Antiarrhythmic Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
    - Sodium Channel Blockers
    - Beta Blockers
    - Potassium Channel Blockers
    - Calcium Channel Blockers
    - Other
  - North America Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
    - Oral
    - Parenteral
    - Other
  - North America Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
    - Hospital Pharmacies
    - Retail Pharmacies
    - Other
  - U.S.
    - U.S. Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
      - Sodium Channel Blockers
      - Beta Blockers
      - Potassium Channel Blockers
      - Calcium Channel Blockers
      - Other
    - U.S. Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Other
    - U.S. Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacies
      - Retail Pharmacies
      - Other
  - Canada
    - Canada Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
      - Sodium Channel Blockers
      - Beta Blockers
      - Potassium Channel Blockers
      - Calcium Channel Blockers
      - Other
    - Canada Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Other
    - Canada Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacies
      - Retail Pharmacies
      - Other
- Europe
  - Europe Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
    - Sodium Channel Blockers
    - Beta Blockers
    - Potassium Channel Blockers
    - Calcium Channel Blockers
    - Other
  - Europe Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
    - Oral
    - Parenteral
    - Other
  - Europe Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
    - Hospital Pharmacies
    - Retail Pharmacies
    - Other
  - Germany
    - Germany Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
      - Sodium Channel Blockers
      - Beta Blockers
      - Potassium Channel Blockers
      - Calcium Channel Blockers
      - Other
    - Germany Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Other
    - Germany Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacies
      - Retail Pharmacies
      - Other
  - UK
    - UK Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
      - Sodium Channel Blockers
      - Beta Blockers
      - Potassium Channel Blockers
      - Calcium Channel Blockers
      - Other
    - UK Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Other
    - UK Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacies
      - Retail Pharmacies
      - Other
  - France
    - France Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
      - Sodium Channel Blockers
      - Beta Blockers
      - Potassium Channel Blockers
      - Calcium Channel Blockers
      - Other
    - France Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Other
    - France Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacies
      - Retail Pharmacies
      - Other
  - Italy
    - Italy Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
      - Sodium Channel Blockers
      - Beta Blockers
      - Potassium Channel Blockers
      - Calcium Channel Blockers
      - Other
    - Italy Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Other
    - Italy Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacies
      - Retail Pharmacies
      - Other
  - Spain
    - Spain Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
      - Sodium Channel Blockers
      - Beta Blockers
      - Potassium Channel Blockers
      - Calcium Channel Blockers
      - Other
    - Spain Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Other
    - Spain Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacies
      - Retail Pharmacies
      - Other
  - Denmark
    - Denmark Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
      - Sodium Channel Blockers
      - Beta Blockers
      - Potassium Channel Blockers
      - Calcium Channel Blockers
      - Other
    - Denmark Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Other
    - Denmark Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacies
      - Retail Pharmacies
      - Other
  - Sweden
    - Sweden Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
      - Sodium Channel Blockers
      - Beta Blockers
      - Potassium Channel Blockers
      - Calcium Channel Blockers
      - Other
    - Sweden Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Other
    - Sweden Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacies
      - Retail Pharmacies
      - Other
  - Norway
    - Norway Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
      - Sodium Channel Blockers
      - Beta Blockers
      - Potassium Channel Blockers
      - Calcium Channel Blockers
      - Other
    - Norway Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Other
    - Norway Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacies
      - Retail Pharmacies
      - Other
- Asia Pacific
  - Asia Pacific Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
    - Sodium Channel Blockers
    - Beta Blockers
    - Potassium Channel Blockers
    - Calcium Channel Blockers
    - Other
  - Asia Pacific Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
    - Oral
    - Parenteral
    - Other
  - Asia Pacific Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
    - Hospital Pharmacies
    - Retail Pharmacies
    - Other
  - China
    - China Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
      - Sodium Channel Blockers
      - Beta Blockers
      - Potassium Channel Blockers
      - Calcium Channel Blockers
      - Other
    - China Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Other
    - China Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacies
      - Retail Pharmacies
      - Other
  - Japan
    - Japan Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
      - Sodium Channel Blockers
      - Beta Blockers
      - Potassium Channel Blockers
      - Calcium Channel Blockers
      - Other
    - Japan Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Other
    - Japan Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacies
      - Retail Pharmacies
      - Other
  - India
    - India Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
      - Sodium Channel Blockers
      - Beta Blockers
      - Potassium Channel Blockers
      - Calcium Channel Blockers
      - Other
    - India Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Other
    - India Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacies
      - Retail Pharmacies
      - Other
  - South Korea
    - South Korea Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
      - Sodium Channel Blockers
      - Beta Blockers
      - Potassium Channel Blockers
      - Calcium Channel Blockers
      - Other
    - South Korea Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Other
    - South Korea Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacies
      - Retail Pharmacies
      - Other
  - Australia
    - Australia Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
      - Sodium Channel Blockers
      - Beta Blockers
      - Potassium Channel Blockers
      - Calcium Channel Blockers
      - Other
    - Australia Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Other
    - Australia Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacies
      - Retail Pharmacies
      - Other
  - Thailand
    - Thailand Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
      - Sodium Channel Blockers
      - Beta Blockers
      - Potassium Channel Blockers
      - Calcium Channel Blockers
      - Other
    - Thailand Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Other
    - Thailand Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacies
      - Retail Pharmacies
      - Other
- Latin America
  - Latin America Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
    - Sodium Channel Blockers
    - Beta Blockers
    - Potassium Channel Blockers
    - Calcium Channel Blockers
    - Other
  - Latin America Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
    - Oral
    - Parenteral
    - Other
  - Latin America Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
    - Hospital Pharmacies
    - Retail Pharmacies
    - Other
  - Brazil
    - Brazil Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
      - Sodium Channel Blockers
      - Beta Blockers
      - Potassium Channel Blockers
      - Calcium Channel Blockers
      - Other
    - Brazil Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Other
    - Brazil Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacies
      - Retail Pharmacies
      - Other
  - Argentina
    - Argentina Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
      - Sodium Channel Blockers
      - Beta Blockers
      - Potassium Channel Blockers
      - Calcium Channel Blockers
      - Other
    - Argentina Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Other
    - Argentina Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacies
      - Retail Pharmacies
      - Other
- Middle East and Africa (MEA)
  - Middle East and Africa Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
    - Sodium Channel Blockers
    - Beta Blockers
    - Potassium Channel Blockers
    - Calcium Channel Blockers
    - Other
  - Middle East and Africa Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
    - Oral
    - Parenteral
    - Other
  - Middle East and Africa Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
    - Hospital Pharmacies
    - Retail Pharmacies
    - Other
  - South Africa
    - South Africa Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
      - Sodium Channel Blockers
      - Beta Blockers
      - Potassium Channel Blockers
      - Calcium Channel Blockers
      - Other
    - South Africa Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Other
    - South Africa Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacies
      - Retail Pharmacies
      - Other
  - Saudi Arabia
    - Saudi Arabia Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
      - Sodium Channel Blockers
      - Beta Blockers
      - Potassium Channel Blockers
      - Calcium Channel Blockers
      - Other
    - Saudi Arabia Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Other
    - Saudi Arabia Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacies
      - Retail Pharmacies
      - Other
  - UAE
    - UAE Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
      - Sodium Channel Blockers
      - Beta Blockers
      - Potassium Channel Blockers
      - Calcium Channel Blockers
      - Other
    - UAE Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Other
    - UAE Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacies
      - Retail Pharmacies
      - Other
  - Kuwait
    - Kuwait Antiarrhythmic Drugs Outlook (Revenue, USD Million, 2018 - 2030)
      - Sodium Channel Blockers
      - Beta Blockers
      - Potassium Channel Blockers
      - Calcium Channel Blockers
      - Other
    - Kuwait Antiarrhythmic Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Parenteral
      - Other
    - Kuwait Antiarrhythmic Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacies
      - Retail Pharmacies
      - Other

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Quantitative Analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.